Raymond James & Associates Fibrogen Inc Transaction History

Raymond James & Associates

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 14, 2023	SELL	$15.95 - $25.18 $11,659 - $18,406	-731 Reduced 1.38%	52,246 $974,000
Q4 2022 Feb 08, 2023	BUY	$13.27 - $17.73 $262,852 - $351,195	19,808 Added 59.72%	52,977 $848,000
Q3 2022 Oct 25, 2022	SELL	$11.4 - $14.6 $15,960 - $20,440	-1,400 Reduced 4.05%	33,169 $432,000
Q2 2022 Aug 12, 2022	BUY	$7.94 - $12.96 $6,352 - $10,368	800 Added 2.37%	34,569 $365,000
Q1 2022 May 11, 2022	SELL	$12.02 - $16.79 $20,434 - $28,543	-1,700 Reduced 4.79%	33,769 $406,000
Q4 2021 Feb 08, 2022	SELL	$9.93 - $15.39 $9,443 - $14,635	-951 Reduced 2.61%	35,469 $500,000
Q3 2021 Nov 02, 2021	BUY	$10.18 - $26.64 $631 - $1,651	62 Added 0.17%	36,420 $372,000
Q2 2021 Aug 11, 2021	BUY	$18.57 - $35.68 $675,168 - $1.3 Million	36,358 New	36,358 $968,000
Q2 2019 Aug 06, 2019	SELL	$35.13 - $55.53 $544,936 - $861,381	-15,512 Closed	0 $0
Q1 2019 May 06, 2019	BUY	$42.83 - $59.91 $172,819 - $241,736	4,035 Added 35.16%	15,512 $843,000
Q4 2018 Feb 11, 2019	SELL	$37.97 - $60.16 $55,853 - $88,495	-1,471 Reduced 11.36%	11,477 $531,000
Q3 2018 Nov 14, 2018	SELL	$56.3 - $67.25 $12,723 - $15,198	-226 Reduced 1.72%	12,948 $787,000
Q2 2018 Aug 14, 2018	BUY	$44.9 - $64.95 $73,636 - $106,518	1,640 Added 14.22%	13,174 $825,000
Q1 2018 May 14, 2018	BUY	$45.35 - $61.65 $30,928 - $42,045	682 Added 6.28%	11,534 $533,000
Q4 2017 Feb 14, 2018	SELL	$41.95 - $60.1 $118,550 - $169,842	-2,826 Reduced 20.66%	10,852 $514,000
Q3 2017 Nov 13, 2017	BUY	$33.4 - $53.9 $456,845 - $737,244	13,678	13,678 $736,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $31.9M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.